Evidence map›Paper›PMID 39213469›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2024

Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis.

Pablo Villoslada, Elisabeth Solana, Salut Alba-Arbalat, Eloy Martinez-Heras, Francesc Vivo, Elisabet Lopez-Soley, Alberto Calvi, Anna Camos-Carreras, Marina Dotti-Boada, Rafel Alcubierre Bailac and 4 more

Abstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pablo VillosladaFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0002-8735-6119
Elisabeth SolanaFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0001-7973-2439
Salut Alba-ArbalatFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.
Eloy Martinez-HerasFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0001-9937-3162
Francesc VivoFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.
Elisabet Lopez-SoleyFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.
Alberto CalviFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0002-1953-2803
Anna Camos-CarrerasFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.
Marina Dotti-BoadaFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0002-8444-2927
Rafel Alcubierre BailacFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.
Elena H Martinez-LapiscinaFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0003-4272-0826
Yolanda BlancoFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0002-1834-0498
Sara LlufriuFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0003-4273-9121
Bernardo F Sanchez DalmauFrom the Department of Neurology (P.V.), Hospital Hospital del Mar-Pomepu Fabra University, Barcelona; Neurology Service and Laboratory of Advanced Imaging in Neuroimmunological Diseases (E.S., S.A.-A., E.M.-H., F.V., E.L.-S., A.C., E.H.M.-L., Y.B., S.L.), Hospital Clinic of Barcelona; and Ophthalmology Service (S.A.-A., A.C.-C., M.D.-B., R.A.B., S.L., B.F.S.D.), Hospital Clinic of Barcelona, Spain.ORCID 0000-0001-8950-9759

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesRecovery of vision after acute optic neuritis (AON) is critical to improving the quality of life of people with demyelinating diseases. The objective of the study was to prospectively assess the changes in visual acuity, retinal layer thickness, and cortical visual network in patients with AON to identify the predictors of permanent visual disability.

methodsWe studied a prospective cohort of 88 consecutive patients with AON with 6-month follow-up using high and low-contrast (2.5%) visual acuity, color vision, retinal thickness from optical coherence tomography, latencies and amplitudes of multifocal visual evoked potentials, mean deviation of visual fields, and diffusion-based structural (n = 53) and functional (n = 19) brain MRI to analyze the cortical visual network. The primary outcome was 2.5% low-contrast vision, and data were analyzed with mixed-effects and multivariate regression models.

resultsWe found that after 6 months, low-contrast vision and quality of vision remained moderately impaired. The thickness of the ganglion cell layer at baseline was a predictor of low-contrast vision 6 months later (ß = 0.49 [CI 0.11-0.88], DISCUSSION: The assessment of the visual pathway at baseline predicts permanent vision disability after AON, indicating that damage is produced early after disease onset and that it can be used for defining vision impairment and guiding therapy.

Indexed as

Optic NeuritisRecovery of FunctionTomography, Optical CoherenceAdultEvoked Potentials, VisualFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesRetinaVision DisordersVisual AcuityVisual Cortex

Identifiers

PMID39213469
PMCPMC11368233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.